Vemurafenib (PLX4032): An orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma;Vemurafenib (PLX4032): Un Inhibidor de BRAF mutado disponible por vía oral para el tratamiento del melanoma metastático

Annals of Pharmacotherapy

Volumn 45, Issue 11, 2011, Pages 1399-1405

  Heakal, Yasser ^a   Kester, Mark ^b   Savage, Scott ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c University of North Carolina   (United States)

Author keywords

Melanoma; PLX4032; RG7204; RO5185426; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DACARBAZINE; GSK 2118436; IPILIMUMAB; SORAFENIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ALOPECIA; AREA UNDER THE CURVE; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; REVIEW; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 80155161402     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q363     Document Type: Review

References (44)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
2. Miller AJ, Mihm, MC Jr., Melanoma. N Engl J Med 2006;355:51-65.
3. American Cancer Society. Melanoma skin cancer. www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics (accessed 2011 Jul 22).
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26.
6. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011;17:297-303.
7. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26: 3291-310.
8. Cox AD, Der CJ. Ras history: the saga continues. Small Gtpases 2010;1: 2-27.
9. Flaherty KT, McArthur G. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 2010;116:4902-13.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
11. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
12. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
13. Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-27.
14. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
15. FDA news release. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm (accessed 2011 Aug 23).
16. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
17. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9.
18. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011;8:426-33.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
20. A study of the effect of food on the pharmacokinetics of single dose RO5185426 and the safety and efficacy of continuous administration in patients with BRAF V600E mutation-positive metastatic melanoma. http://clinicaltrials.gov/ct2/show/NCT01264380?term=nct01264380&rank=1 (accessed 2011 Jul 22).
21. A pharmacokinetic study of RO5185426 in combination with a drug cocktail in patients with metastatic melanoma. http://clinicaltrials.gov/ct2/show/NCT01001299?term=plx4032&rank=6 (accessed 2011 Jul 22).
22. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multi center phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma (abstract 8509). J Clin Oncol 2011;29(suppl; abstract 8509).
23. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364;2507-16.
24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
25. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109:5011-5.
26. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7.
27. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72.
28. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
29. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
30. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) (abstract CRA8503J). Clin Oncol 2011; 29(suppl; abstract CRA8503).
31. Kaiser J. Combining targeted drugs to stop resistant tumors. Science 2011;331:1542-5.
32. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011;71:2750-60.
33. De Angelis C. Side effects related to systemic cancer treatment: are we changing the promethean experience with molecularly targeted therapies? Curr Oncol 2008;15:198.
34. Lynch MC, Straub R, Adams DR. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. J Drugs Dermatol 2011;10:308-10.
35. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-61.
36. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors (abstract 8503). J Clin Oncol 2010;28(suppl):15s.
37. Postel-Vinay S, Gomez-Roca C, Molife LR, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 2011;29:1728-35.
38. A study of vemurafenib in metastatic melanoma patients with brain metastases. http://clinicaltrials.gov/ct2/show/NCT01378975?term=vemurafenib&rank=2 (accessed 2011 Jul 22).
39. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases (abstract 8548). J Clin Oncol 2011;29(suppl;abstract 8548).
40. Malakoff D. Can treatment costs be tamed? Science 2011;331:1545-7.
41. medpage Today. FDA OKs late-stage melanoma drug. www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/28083 (accessed 2011 Aug 23).
42. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009;101:1182-92.
43. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
44. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011;8:135-41.